Managing anaplastic thyroid carcinoma

Ejigayehu G. Abate; Robert C. Smallridge

doi:10.1586/eem.11.76

Managing anaplastic thyroid carcinoma

Ejigayehu G. Abate, Robert C. Smallridge

Endocrinology

Research output: Contribution to journal › Review article › peer-review

2 Scopus citations

Abstract

Anaplastic thyroid cancer is one of the most lethal malignancies, with dismal prognosis, resistance to multimodal treatments and a median survival of only 5-6 months. Advances in the discovery of genetic pathway aberrations involved in this aggressive disease have been made, and multiple novel therapies targeting these pathways are undergoing clinical trials. So far, there is no single effective treatment for this disease; however, multimodal therapies with a combination of surgery, radiation and chemotherapy hold some promise. We conducted a PubMed search using the words thyroid neoplasm, anaplastic thyroid carcinoma, anaplastic thyroid cancer and anaplastic thyroid neoplasm, revealing 1673 publications. We review the pathophysiology, current treatments and advances made in identifying the alterations in genetic pathways, as well as novel therapies targeting these pathways.

Original language	English (US)
Pages (from-to)	793-809
Number of pages	17
Journal	Expert Review of Endocrinology and Metabolism
Volume	6
Issue number	6
DOIs	https://doi.org/10.1586/eem.11.76
State	Published - Nov 2011

Keywords

anaplastic thyroid carcinoma
multimodal treatments
novel therapy
pathogenesis
signaling pathways
staging
targeted therapy

ASJC Scopus subject areas

Endocrinology, Diabetes and Metabolism

Access to Document

10.1586/eem.11.76

Cite this

@article{6274624b7231470c97b466cb7a356d18,

title = "Managing anaplastic thyroid carcinoma",

abstract = "Anaplastic thyroid cancer is one of the most lethal malignancies, with dismal prognosis, resistance to multimodal treatments and a median survival of only 5-6 months. Advances in the discovery of genetic pathway aberrations involved in this aggressive disease have been made, and multiple novel therapies targeting these pathways are undergoing clinical trials. So far, there is no single effective treatment for this disease; however, multimodal therapies with a combination of surgery, radiation and chemotherapy hold some promise. We conducted a PubMed search using the words thyroid neoplasm, anaplastic thyroid carcinoma, anaplastic thyroid cancer and anaplastic thyroid neoplasm, revealing 1673 publications. We review the pathophysiology, current treatments and advances made in identifying the alterations in genetic pathways, as well as novel therapies targeting these pathways.",

keywords = "anaplastic thyroid carcinoma, multimodal treatments, novel therapy, pathogenesis, signaling pathways, staging, targeted therapy",

author = "Abate, {Ejigayehu G.} and Smallridge, {Robert C.}",

note = "Funding Information: Editorial Director, Future Science Group, London, UK. Disclosure: Elisa Manzotti has disclosed no relevant financial relationships. CME Author Laurie Barclay, MD Freelance writer and reviewer, Medscape, LLC. Disclosure: Laurie Barclay has disclosed no relevant financial relationships. Authors and Credentials Ejigayehu G Abate, MD Division of Endocrinology, Department of Internal Medicine, Mayo Clinic, Jacksonville, Florida, USA. Disclosure: Ejigayehu G Abate has disclosed no relevant financial relationships. Robert C Smallridge, MD Division of Endocrinology, Department of Internal Medicine, Mayo Clinic, Jacksonville, Florida, USA. Disclosure: Robert C Smallridge is the principal investigator in a Phase I clinical trial for anaplastic thyroid cancer sponsored by Daiichi-Sankyo. This work was supported in part by Mayo Clinic, NIH grant R01CA136665 (RCS), the Bankhead-Coley Cancer Research Program, Florida Department of Health (RCS) and a generous gift from Alfred D and Audrey M Petersen.",

year = "2011",

month = nov,

doi = "10.1586/eem.11.76",

language = "English (US)",

volume = "6",

pages = "793--809",

journal = "Expert Review of Endocrinology and Metabolism",

issn = "1744-6651",

publisher = "Expert Reviews Ltd.",

number = "6",

}

TY - JOUR

T1 - Managing anaplastic thyroid carcinoma

AU - Abate, Ejigayehu G.

AU - Smallridge, Robert C.

N1 - Funding Information: Editorial Director, Future Science Group, London, UK. Disclosure: Elisa Manzotti has disclosed no relevant financial relationships. CME Author Laurie Barclay, MD Freelance writer and reviewer, Medscape, LLC. Disclosure: Laurie Barclay has disclosed no relevant financial relationships. Authors and Credentials Ejigayehu G Abate, MD Division of Endocrinology, Department of Internal Medicine, Mayo Clinic, Jacksonville, Florida, USA. Disclosure: Ejigayehu G Abate has disclosed no relevant financial relationships. Robert C Smallridge, MD Division of Endocrinology, Department of Internal Medicine, Mayo Clinic, Jacksonville, Florida, USA. Disclosure: Robert C Smallridge is the principal investigator in a Phase I clinical trial for anaplastic thyroid cancer sponsored by Daiichi-Sankyo. This work was supported in part by Mayo Clinic, NIH grant R01CA136665 (RCS), the Bankhead-Coley Cancer Research Program, Florida Department of Health (RCS) and a generous gift from Alfred D and Audrey M Petersen.

PY - 2011/11

Y1 - 2011/11

N2 - Anaplastic thyroid cancer is one of the most lethal malignancies, with dismal prognosis, resistance to multimodal treatments and a median survival of only 5-6 months. Advances in the discovery of genetic pathway aberrations involved in this aggressive disease have been made, and multiple novel therapies targeting these pathways are undergoing clinical trials. So far, there is no single effective treatment for this disease; however, multimodal therapies with a combination of surgery, radiation and chemotherapy hold some promise. We conducted a PubMed search using the words thyroid neoplasm, anaplastic thyroid carcinoma, anaplastic thyroid cancer and anaplastic thyroid neoplasm, revealing 1673 publications. We review the pathophysiology, current treatments and advances made in identifying the alterations in genetic pathways, as well as novel therapies targeting these pathways.

AB - Anaplastic thyroid cancer is one of the most lethal malignancies, with dismal prognosis, resistance to multimodal treatments and a median survival of only 5-6 months. Advances in the discovery of genetic pathway aberrations involved in this aggressive disease have been made, and multiple novel therapies targeting these pathways are undergoing clinical trials. So far, there is no single effective treatment for this disease; however, multimodal therapies with a combination of surgery, radiation and chemotherapy hold some promise. We conducted a PubMed search using the words thyroid neoplasm, anaplastic thyroid carcinoma, anaplastic thyroid cancer and anaplastic thyroid neoplasm, revealing 1673 publications. We review the pathophysiology, current treatments and advances made in identifying the alterations in genetic pathways, as well as novel therapies targeting these pathways.

KW - anaplastic thyroid carcinoma

KW - multimodal treatments

KW - novel therapy

KW - pathogenesis

KW - signaling pathways

KW - staging

KW - targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=80054867613&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80054867613&partnerID=8YFLogxK

U2 - 10.1586/eem.11.76

DO - 10.1586/eem.11.76

M3 - Review article

AN - SCOPUS:80054867613

SN - 1744-6651

VL - 6

SP - 793

EP - 809

JO - Expert Review of Endocrinology and Metabolism

JF - Expert Review of Endocrinology and Metabolism

IS - 6

ER -

Managing anaplastic thyroid carcinoma

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this